AstraZeneca announced Monday the appointment of Sean Bohen as chief medical officer and executive vice president of global medicines development effective September 15. Bohen most recently held the position of senior vice president of early development at Roche's Genentech unit, where he was responsible for delivering trial-ready drug candidates to late-stage development across a number of therapy areas.
According to the drugmaker, Bohen will be responsible for driving the progress of AstraZeneca's portfolio of experimental small-molecule and biologic drugs through late-stage development to regulatory approval. Meanwhile, Bohen will also be responsible for patient safety across the entire AstraZeneca and Medimmune portfolio.
AstraZeneca CEO Pascal Soriot remarked Bohen "is a tremendous scientist and an accomplished drug developer. His impressive expertise in key areas of our exciting pipeline, including oncology and immunology, will further strengthen and accelerate the delivery of new medicines." Soriot added "his extensive diagnostics experience will also reinforce our efforts in precision medicine."
Bohen fills the role vacated by Briggs Morrison, who left the drugmaker earlier this year and was later named as CEO of Syndax Pharmaceuticals. For related analysis, see Spotlight On: Syndax Pharmaceuticals unveils star signing from AstraZeneca – what Morrison's career change says about the biotech and pharma markets.
To read more Top Story articles, click here.